tirzepatide meta analysis EASD 2023: meta-analysis shows superiority to semaglutide Tirzepatide compared to SC #semaglutide

Con el avance de nuevos estudios clnicos y la aceleracin de su desarrollo internacional, se espera que esta clase teraputica ample las opciones de tratamiento para la diabetes tipo 2, la obesidad y otras enfermedades metablicas a nivel mundial

doi: 10.3389/fimmu.2022.985861 41 RichardsCEVellankiSHSmithYEHopkinsAM

That dual action means the body breaks down existing belly fat while making it harder to deposit new fat in the abdominal compartment

Semaglutide reduces appetite and slows digestion, but it doesn't eliminate calorie counting

And a separate study in The New England Journal of Medicine found that 59 percent of patients with NASH who took a high dose of semaglutide for 72 weeks saw an improvement in their condition without worsening of fibrosis

Pei M, Chen D, Li J, Wei L